Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Treatment + Pancreatic Cancer (4 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

Treatment:
Breast
Ovarian
Pancreatic
Prostate

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.   

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

Treatment:
Breast
Melanoma
Ovarian
Pancreatic
Prostate

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. 

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

Treatment:
Breast
Ovarian
Pancreatic
Prostate

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. 

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

Treatment:
Breast
Ovarian
Pancreatic

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

This study is looking at how well two cancer drugs work together to treat certain advanced cancers. 

The researchers want to learn how safe and effective the combination of an immunotherapy (known as Avelumab) and a PARP inhibitor (known as Talazoparib) is for treating patients with locally advanced or metastatic solid tumors with a BRCA1, BRCA2, or ATM gene defect.

Additional Results on Clinicaltrials.gov: Treatment + Pancreatic Cancer

186 Results

Clinical Trial Official Title
NCT01972919 Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer
NCT04193904 A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
NCT02128100 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
NCT03716531 Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT03492671 Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT03104439 Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT04452357 Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
NCT02598349 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT02454140 Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer
NCT04050085 SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
NCT03704662 Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable Pancreatic Adenocarcinoma
NCT02599662 Intraoperative Radiation Therapy for Resectable Pancreas Cancer
NCT04484909 NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT02337465 KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
NCT04106856 Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
NCT02648282 Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer
NCT03991962 Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03652428 Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT03073785 Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
NCT03600623 Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
NCT03885284 Study of Proton Therapy in Adjuvant Pancreatic Cancer
NCT02451982 Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer
NCT03536208 Biological Effect of Warfarin on Pancreatic Cancer
NCT03109041 Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
NCT01088789 A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
NCT03161379 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
NCT03956056 Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
NCT03572283 Bethanechol Prior to Pancreatic Surgery
NCT04115254 Stereotactic Magnetic Resonance Guided Radiation Therapy
NCT02173353 Feasibility of Using Ultrasound to Track Respiration Motion
NCT03621644 Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
NCT03187951 PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer
NCT03322995 Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
NCT02515513 The Role of Muscle Cachexia in Pancreatic Cancer
NCT03384238 Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT03623984 Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
NCT02843945 Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT03601923 Niraparib in Patients With Pancreatic Cancer
NCT03281382 Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
NCT04191421 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
NCT03523312 Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
NCT03711890 Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT03745794 Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT03563248 Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT02902484 Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
NCT03307564 Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
NCT03970252 Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT04161755 Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
NCT02863783 EUS Fiducial for Pancreas Surgery
NCT02672917 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT03856658 Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT04008537 Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT03519308 A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
NCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT03373188 VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
NCT03138720 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
NCT04005690 Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
NCT02047474 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
NCT03323489 Celiac Plexus Radio-Surgery for Pain Management
NCT03086642 Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
NCT04157127 Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03977233 Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT02757859 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT03006302 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
NCT03634332 Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
NCT03168737 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
NCT04270929 Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
NCT03095781 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT04147494 Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT02070705 DCE MRI in Patients With Pancreatic Cancer
NCT03434678 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
NCT03269994 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
NCT02079740 Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
NCT04007744 Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
NCT03257761 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT02723331 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
NCT04222413 Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT04117087 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
NCT03147768 Laser Tissue Welding - Distal Pancreatectomy Sealing Study
NCT01365169 Post-op Wellness Program for Pancreatic Cancer Patients That Uses Patient Feedback and Real-time Provider Monitoring
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03376659 Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT03816358 Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
NCT04267575 Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
NCT03264404 Azacitidine and Pembrolizumab in Pancreatic Cancer
NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
NCT03623464 RCT of Mobile Apps & FitBit v. Usual Care
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT03552718 QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NCT02446093 Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma
NCT03714555 Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
NCT03899636 A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03649321 Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer
NCT03935893 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03190941 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT03745326 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
NCT03190265 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
NCT04449679 Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
NCT03883919 Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
NCT03767582 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT03611309 Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
NCT03703063 Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
NCT04098081 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT02905578 A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02671890 Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer
NCT03250273 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
NCT04046887 Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT04068896 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
NCT03785210 Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
NCT03535727 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT03910387 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03410030 Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
NCT03153410 Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
NCT02451553 Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
NCT03425279 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Solid Tumors
NCT03484299 Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03553004 Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
NCT04426669 A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT03953235 A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
NCT03727880 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
NCT03825289 Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03576131 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
NCT03404960 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
NCT03184870 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
NCT02433626 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT01845805 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)
NCT00720785 Natural Killer Cells and Bortezomib to Treat Cancer
NCT03637491 A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer
NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT03058289 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT03512756 A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer
NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
NCT04233866 Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT03412799 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01676259 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04207944 The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT04429542 Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
NCT03205176 AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
NCT03415854 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
NCT03854110 Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03816163 A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
NCT03784677 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
NCT02744287 Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
NCT03682289 Phase II Trial of AZD6738 Alone and in Combination With Olaparib
NCT03126435 EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03829436 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
NCT03504423 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
NCT02595424 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
NCT03368963 TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT03375320 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT01954992 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT03678883 9-ING-41 in Patients With Advanced Cancers
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT03337087 Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
NCT04148937 A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
NCT03565445 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT03077685 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NCT01643460 Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
NCT03736720 Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
NCT04319757 ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT04329949 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT04171700 A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
NCT03884556 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

FORCE:Facing Our Risk of Cancer Empowered